Research analysts covering Clearmind Medicine.
Recent press releases and 8-K filings for CMND.
Clearmind Medicine Advances CMND-100 to Dosing Phase in AUD Clinical Trial
CMND
New Projects/Investments
- Clearmind Medicine Inc. announced a key milestone in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD).
- The first participant has been enrolled and dosed with CMND-100, its proprietary MEAI-based oral drug candidate, at Hadassah-University Medical Center in Jerusalem, Israel.
- This advancement follows positive top-line results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board to continue the trial.
5 days ago
Clearmind Medicine Inc. Announces Registered Direct Offering
CMND
Equity Offering
New Projects/Investments
- Clearmind Medicine Inc. entered into a definitive securities purchase agreement on November 26, 2025, for a registered direct offering with investors.
- The offering includes the sale of 7,944,868 common shares at $0.12 per share and pre-funded warrants to purchase up to 2,865,960 common shares at $0.1199 per pre-funded warrant.
- The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common share and will not expire until exercised in full, subject to a 4.99% beneficial ownership limitation.
- The company expects to receive approximately $1.294 million in aggregate gross proceeds from the offering, which will be used for general corporate purposes, including operating expenses, research and development, working capital, and potential acquisitions.
Nov 26, 2025, 1:48 PM
Clearmind Medicine Initiates Patient Enrollment at Tel Aviv Sourasky Medical Center for CMND-100 AUD Trial
CMND
New Projects/Investments
- Clearmind Medicine Inc. has commenced patient enrollment at the Tel Aviv Sourasky Medical Center (TASMC) for its FDA-approved multinational Phase I/IIa clinical trial of CMND-100 in Alcohol Use Disorder (AUD).
- The activation of TASMC as a trial site, under Principal Investigator Prof. David Zeltser, expands the network of participating centers, which also includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center.
- The Phase I/IIa trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, which is Clearmind's proprietary, non-hallucinogenic, oral MEAI-based compound.
- Recent top-line results from the first completed cohort of the trial showed excellent safety and adherence with no serious adverse events.
Nov 25, 2025, 9:01 PM
Clearmind Medicine Activates Fifth Clinical Trial Site for CMND-100
CMND
New Projects/Investments
- Clearmind Medicine Inc. has activated Hadassah Medical Center in Jerusalem, Israel, as the fifth global medical site for its FDA-approved Phase I/IIa clinical trial for CMND-100.
- CMND-100 is a proprietary non-hallucinogenic MEAI-based oral drug candidate developed to address Alcohol Use Disorder (AUD).
- The multinational, multi-center study evaluates the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption.
- Top-line data from the first cohort of the clinical trial showed a favorable safety profile with no serious adverse events reported, and the treatment was generally well-tolerated across all participants.
Nov 20, 2025, 1:08 PM
Clearmind Medicine Inc. Announces $2.185 Million Registered Direct Offering
CMND
New Projects/Investments
M&A
- Clearmind Medicine Inc. entered into a securities purchase agreement on November 19, 2025, for a registered direct offering of 10,925,000 common shares at a purchase price of $0.20 per Common Share.
- The offering is expected to close on or about November 20, 2025, with anticipated aggregate gross proceeds to the company of approximately $2.185 million.
- The net proceeds from the offering will be used for general corporate purposes, which may include operating expenses, research and development (including clinical and pre-clinical testing of product candidates), working capital, future acquisitions, and general capital expenditures.
Nov 19, 2025, 11:09 AM
Clearmind Medicine Announces Positive Top-Line Results from Phase I/IIa Clinical Trial
CMND
New Projects/Investments
- Clearmind Medicine Inc. announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder (AUD).
- The first cohort demonstrated a favorable safety profile, with no serious adverse events reported, and the treatment was generally well-tolerated by all participants.
- The trial also showed strong treatment observance and high adherence to the dosing regimen and protocol requirements.
- These early findings support the ongoing evaluation of CMND-100 as a potential breakthrough therapy for AUD.
Nov 18, 2025, 9:16 PM
Clearmind Medicine Inc. Announces Registered Direct Offering
CMND
- Clearmind Medicine Inc. entered into a Securities Purchase Agreement on November 17, 2025, for a registered direct offering of common shares and pre-funded warrants.
- The offering includes 3,991,768 common shares at $0.25 per share and pre-funded warrants to purchase 1,518,000 common shares at $0.2499 per warrant.
- The pre-funded warrants are immediately exercisable at $0.0001 per common share and do not expire until exercised in full.
- The offering is expected to generate approximately $1.377 million in aggregate gross proceeds and is anticipated to close on or about November 18, 2025.
- Net proceeds from the offering will be used for general corporate purposes, including operating expenses, research and development, working capital, and future acquisitions.
Nov 17, 2025, 11:15 AM
Clearmind Medicine Receives Final Approval to Expand FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder
CMND
New Projects/Investments
- Clearmind Medicine Inc. received final approval on November 13, 2025, to expand its FDA regulated Phase 1/2a clinical trial for Alcohol Use Disorder (AUD).
- The expansion allows Hadassah Medical Center in Jerusalem, Israel, to join the clinical trial as a leading site.
- The trial is evaluating CMND-100, a proprietary MEAI-based oral drug candidate, with the first cohort treatment successfully completed.
- The study aims to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, and evaluate its preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD.
Nov 13, 2025, 9:01 PM
Clearmind Medicine Announces Registered Direct Offering
CMND
- Clearmind Medicine Inc. entered into a definitive securities purchase agreement on November 13, 2025, for a registered direct offering.
- The offering includes the sale of 958,222 common shares at $0.20 per share and pre-funded warrants to purchase up to 2,984,146 common shares at $0.1999 per warrant.
- The pre-funded warrants are immediately exercisable at $0.0001 per common share and will not expire until fully exercised.
- The company expects to receive approximately $0.788 million in gross proceeds from the offering, which is anticipated to close on or about November 14, 2025.
- Net proceeds from the offering will be used for general corporate purposes, including operating expenses, research and development, working capital, and potential future acquisitions.
Nov 13, 2025, 12:33 PM
Clearmind Medicine Receives Nasdaq Notification Regarding Stockholders' Equity Deficiency
CMND
Delisting/Listing Issues
Convertible Preferred Issuance
- Clearmind Medicine Inc. received a Nasdaq Notification Letter on November 3, 2025, for non-compliance with the minimum stockholders' equity requirement of $2,500,000.
- The company reported stockholders' equity of $1,065,668 for the three and nine months ended July 31, 2025.
- This notification has no immediate effect on the company's Nasdaq listing or business operations, and Clearmind has until December 18, 2025, to submit a plan to regain compliance.
- The company expects to regain compliance if additional convertible promissory notes are converted, following the conversion of $1,045,062 into 885,000 common shares on October 30 and 31, 2025.
Nov 6, 2025, 9:04 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more